Switch theme
Sign up to access all valuation multiples
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both (a) discovery/contract research (CRO) and (b) chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing.
1999
3.1K+
LTM Revenue $204M
LTM EBITDA $49.4M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sai Life Sciences has a last 12-month revenue (LTM) of $204M and a last 12-month EBITDA of $49.4M.
In the most recent fiscal year, Sai Life Sciences achieved revenue of $198M and an EBITDA of $51.8M.
Sai Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sai Life Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $204M | XXX | $198M | XXX | XXX | XXX |
| Gross Profit | $148M | XXX | $144M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $49.4M | XXX | $51.8M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $32.2M | XXX | $31.3M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $21.3M | XXX | $19.9M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sai Life Sciences's stock price is INR 757 (or $9).
Sai Life Sciences has current market cap of INR 158B (or $1.8B), and EV of INR 156B (or $1.8B).
See Sai Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.8B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sai Life Sciences has market cap of $1.8B and EV of $1.8B.
Sai Life Sciences's trades at 9.5x EV/Revenue multiple, and 38.0x EV/EBITDA.
Equity research analysts estimate Sai Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sai Life Sciences has a P/E ratio of 86.8x.
See valuation multiples for Sai Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | 37.0x | XXX | 38.0x | XXX | XXX | XXX |
| EV/EBIT | 56.7x | XXX | 63.5x | XXX | XXX | XXX |
| EV/Gross Profit | 12.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 86.8x | XXX | 106.4x | XXX | XXX | XXX |
| EV/FCF | -39.4x | XXX | -739.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSai Life Sciences's last 12 month revenue growth is 17%
Sai Life Sciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $36K for the same period.
Sai Life Sciences's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sai Life Sciences's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sai Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | 42% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sai Life Sciences acquired XXX companies to date.
Last acquisition by Sai Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Sai Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sai Life Sciences founded? | Sai Life Sciences was founded in 1999. |
| Where is Sai Life Sciences headquartered? | Sai Life Sciences is headquartered in India. |
| How many employees does Sai Life Sciences have? | As of today, Sai Life Sciences has 3.1K+ employees. |
| Is Sai Life Sciences publicy listed? | Yes, Sai Life Sciences is a public company listed on NSE. |
| What is the stock symbol of Sai Life Sciences? | Sai Life Sciences trades under SAILIFE ticker. |
| When did Sai Life Sciences go public? | Sai Life Sciences went public in 2024. |
| Who are competitors of Sai Life Sciences? | Similar companies to Sai Life Sciences include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Sai Life Sciences? | Sai Life Sciences's current market cap is $1.8B |
| What is the current revenue of Sai Life Sciences? | Sai Life Sciences's last 12 months revenue is $204M. |
| What is the current revenue growth of Sai Life Sciences? | Sai Life Sciences revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Sai Life Sciences? | Current revenue multiple of Sai Life Sciences is 8.9x. |
| Is Sai Life Sciences profitable? | Yes, Sai Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sai Life Sciences? | Sai Life Sciences's last 12 months EBITDA is $49.4M. |
| What is Sai Life Sciences's EBITDA margin? | Sai Life Sciences's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Sai Life Sciences? | Current EBITDA multiple of Sai Life Sciences is 37.0x. |
| What is the current FCF of Sai Life Sciences? | Sai Life Sciences's last 12 months FCF is -$46.3M. |
| What is Sai Life Sciences's FCF margin? | Sai Life Sciences's last 12 months FCF margin is -23%. |
| What is the current EV/FCF multiple of Sai Life Sciences? | Current FCF multiple of Sai Life Sciences is -39.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
